No. For the procedure itself, autologous stem cell therapy is not covered by commercial insurance or Medicare. Carriers classify MFAT (micro-fragmented adipose tissue) and BMA (bone marrow aspirate) as investigational for musculoskeletal conditions, so the injection is paid out-of-pocket. HSA and FSA dollars typically apply, because this is a physician-delivered procedure prescribed for a diagnosed condition. Autologous stem cell therapy is performed within the FDA’s 21 CFR 1271 framework for same-day, minimally manipulated procedures, a regulatory category that does not currently trigger reimbursement. On request, Aneesh Garg, DO, CAQ provides a complete superbill for HSA, FSA, or out-of-network submission.
If you are weighing stem cell therapy against a knee replacement, the insurance question matters, but it should not delay an accurate answer about your joint. This page covers what is and isn’t covered, how HSA and FSA apply, and what makes a submission defensible.
The decision
The honest short version: budget for stem cell therapy as a self-pay procedure, then use HSA/FSA and a superbill to recover what your plan allows. Waiting for insurance to catch up is not a plan; the regulatory category behind the gap has not shifted in years, and there is no signal it will shift soon.
What actually changes the math is documentation. A physician-built superbill with CPT and ICD-10 codes, credentials, and a procedure narrative is the difference between a submission your administrator can act on and one that gets returned. We do not promise reimbursement. We build the paperwork to give it a real chance.
Key takeaways
- Stem cell therapy (MFAT and BMA) is self-pay. Carriers classify autologous cell therapy as investigational for musculoskeletal conditions.
- HSA and FSA dollars typically apply, since IRS Publication 502 covers physician-delivered procedures prescribed for a diagnosed condition.
- The superbill is what your administrator reviews: CPT and ICD-10 codes, physician credentials, and a procedure narrative.
- The consultation can often be billed to insurance, even when the procedure itself is out-of-pocket.
- Cherry financing pairs with HSA/FSA, so cost never forces a smaller protocol than your joint needs.
The FDA framework autologous stem cell therapy is performed under: a same-day, minimally manipulated procedure using your own tissue. That regulatory category, not a lack of evidence, is why coverage has not caught up yet.
Why stem cell therapy is self-pay, and what actually helps
The insurance picture is field-wide, not specific to any one clinic. What differs between providers is the documentation you get to submit, and whether a physician matched the right source to your joint.
The regulatory reason coverage hasn’t caught up
Insurance coverage typically follows FDA approval pathways. MFAT and BMA fall outside the FDA-approved drug pathway: your own tissue, harvested and returned in one visit under the FDA’s framework for same-day, minimally manipulated cell procedures (21 CFR 1271), not a manufactured drug or donor product. That category does not currently trigger reimbursement. A 2019 comparison in Stem Cells Translational Medicine found MFAT and bone marrow concentrate produced comparable improvement for knee osteoarthritis, with no significant difference between sources.
How HSA and FSA dollars actually apply
HSA and FSA accounts are designed for qualified medical expenses under IRS Publication 502, and a physician-delivered procedure prescribed for a diagnosed condition generally qualifies. The practical requirement is documentation: proof the procedure was medically indicated, performed by a physician, and coded correctly. Most administrators accept a superbill alone; some also want a letter of medical necessity, which Aneesh Garg, DO, CAQ can provide. Rules vary by administrator, so confirm your plan’s process before you book.
What our superbill includes, and what it doesn’t promise
On request, the superbill includes CPT procedure codes, ICD-10 diagnosis codes tied to your specific indication, physician NPI and credentials, a procedure narrative covering the source selected and the ultrasound guidance used, supporting imaging notes, and an itemized breakdown. Two honest disclaimers: we do not promise reimbursement, that decision belongs to your plan administrator, and we make the documentation as complete and defensible as the protocol behind it.
Paying out-of-pocket: the source is matched to your joint
When care is self-pay, the real question is not only what a procedure costs but which procedure you are buying. Aneesh Garg, DO, CAQ selects MFAT or BMA from your imaging, age, body composition, and stage of arthritis, then co-delivers it with High-Dose PRP and Exosome-Containing Fibrin-Rich Plasma under live ultrasound, never a single commodity injection. Cherry financing pairs with HSA and FSA dollars, so cost does not force a smaller protocol than your tissue needs.
Coverage at a glance, by procedure
How commercial plans and Medicare treat each procedure today. Confirm specifics with your plan administrator.
| Visit type | Insurance | HSA / FSA |
|---|---|---|
| Consultation | In-network only | Yes, typically |
| Stem cell (MFAT or BMA) | No | Yes, typically |
| PRP | No | Yes, typically |
| Shockwave / EMTT | No | Yes, typically |
The bottom line: Every autologous stem cell provider in the country faces the identical FDA pathway. The insurance picture does not separate one clinic from another. The documentation you receive, and the source a physician selects, does.
Frequently asked questions
Is stem cell therapy covered by insurance in Boulder?
No, not for the procedure itself. Autologous stem cell therapy, using MFAT (micro-fragmented adipose tissue) or BMA (bone marrow aspirate), is not currently reimbursed by commercial insurance or Medicare for musculoskeletal indications in the United States. Carriers classify it as investigational, and the procedure is performed within the FDA’s regulatory framework for same-day, minimally manipulated autologous cell procedures (21 CFR 1271), a category that does not currently trigger reimbursement. When Dynamic Athlete is in-network for your plan, we can bill your insurance for the office visit and consultation, but the stem cell procedure itself remains out-of-pocket. HSA and FSA dollars typically apply when the procedure is prescribed for a specific medical indication. On request, we provide complete superbill documentation, including CPT codes, ICD-10 codes, physician credentials, and a procedure narrative, for HSA, FSA, or out-of-network submission. The coverage reality is field-wide, not specific to our clinic.
Can I use HSA or FSA funds for stem cell therapy (MFAT or BMA)?
In most cases, yes. HSA and FSA accounts generally cover qualified medical expenses under IRS Publication 502, which includes physician-delivered procedures such as autologous stem cell therapy, PRP, and shockwave when prescribed for a specific diagnosed condition. What your plan administrator actually needs is documentation: proof that the procedure was medically indicated, performed by a physician, and coded correctly. We provide complete superbill documentation on request, including CPT and ICD-10 codes, physician credentials, and a procedure narrative, and Aneesh Garg, DO, CAQ can supply a letter of medical necessity if your administrator requires one. Because rules vary by plan administrator, confirm your account’s submission process before your procedure, so there are no surprises after you have already paid.
Do you provide a superbill I can submit for reimbursement?
Yes. After your procedure, we provide a complete superbill on request, built for HSA, FSA, and out-of-network insurance submission. It includes CPT procedure codes for every delivered procedure, ICD-10 diagnosis codes tied to your specific indication, the physician NPI and credentials for Aneesh Garg, DO, CAQ, a procedure narrative describing the protocol delivered including source selection and ultrasound guidance, supporting imaging or ultrasound notes documenting the medical indication, and an itemized breakdown tied to the codes. We do not promise reimbursement, because that decision belongs to your plan administrator, not to us. We do make the documentation as complete and defensible as the protocol behind it, which is the single most useful thing you can hand your administrator.
Why isn’t stem cell therapy covered by insurance yet?
Insurance coverage in the United States typically follows FDA approval pathways and Medicare’s national coverage determinations. Autologous stem cell therapy falls outside the FDA-approved drug pathway: MFAT and BMA are your own tissue, harvested and returned in one visit under the FDA’s framework for same-day, minimally manipulated cell procedures (21 CFR 1271), not a manufactured drug or a donor product. That regulatory category does not currently trigger reimbursement, even as the published evidence base for MFAT and BMA in conditions like knee osteoarthritis continues to grow. PRP and shockwave follow a similar pattern: cleared or classified for specific indications but not yet reimbursed for most musculoskeletal applications. Expect this to shift over time as the evidence base expands and payers respond, but for now, budgeting as self-pay is the realistic plan.
Will insurance at least cover the consultation?
It can. When Dynamic Athlete is in-network for your plan, the office visit and consultation are billed to your insurance in the usual way, and only the stem cell procedure itself is out-of-pocket. If your visit is out-of-network, the consultation is self-pay, and it can typically be submitted to HSA or FSA like any other physician visit. Either way, the consultation is where the real decision gets made: whether MFAT or BMA is the right source for your specific joint, or whether stem cell therapy is the right tool for your case at all. Aneesh Garg, DO, CAQ would rather tell you honestly that stem cell therapy is not the answer for your joint than sell a procedure that will not help, so every evaluation starts with imaging-based staging and an honest candidacy assessment.
Does the source, MFAT or BMA, change what I pay?
No. Whether Aneesh Garg, DO, CAQ selects MFAT (your own fat) or BMA (your own bone marrow) for your joint, the insurance and HSA/FSA picture is the same: both are autologous, same-day, minimally manipulated procedures under the same FDA framework, and neither is currently reimbursed by commercial insurance or Medicare for musculoskeletal indications. The source is chosen from your imaging, age, body composition, and the stage of arthritis, never from what a clinic happens to stock. A clinic that only offers one source is not making that decision for you. For the full comparison of how the two sources are matched to a joint, see our guide to MFAT versus BMA as a stem cell source.
What should I ask before I pay out-of-pocket anywhere?
Three questions separate a documentation package built to hold up from one that will not. First: will you provide a complete superbill, CPT codes, ICD-10 codes, physician NPI, and a procedure narrative, on request, before I book? Second: is the consultation billable to my insurance if you are in-network, or is the entire visit out-of-pocket regardless of my plan? Third: does financing, such as Cherry, pair with my HSA or FSA dollars, or do I have to choose only one? A clinic that cannot answer all three clearly is not set up to help you recover what your plan allows. At Dynamic Athlete, the answer to all three is yes, and the documentation reflects the depth of the Dynamic Stem Cell+ protocol actually delivered.
Does Cherry financing work alongside HSA or FSA dollars?
Yes. For patients who prefer to spread the investment over monthly payments, Cherry Technologies financing pairs with HSA and FSA dollars and works alongside your superbill, so cost does not force a smaller protocol than your joint actually needs. This matters specifically for stem cell therapy, where the protocol combines a physician-selected source (MFAT or BMA) with High-Dose PRP and Exosome-Containing Fibrin-Rich Plasma under live ultrasound. The financing conversation and the insurance conversation are separate but complementary: financing addresses cash flow today, while the superbill addresses what you may recover afterward. Ask about both before you book, so the cost conversation never becomes why you delay an accurate evaluation of your joint.
Medically reviewed by Aneesh Garg, DO, CAQ, double board-certified in Sports Medicine and Internal Medicine, physician performing every Dynamic Stem Cell+ and Dynamic PRP+ procedure at Dynamic Athlete. Rated 4.9 out of 5 across 179 Google reviews. This article is educational and does not replace an individualized medical evaluation.
Get an honest read on your joint, then a documentation package built to hold up. Imaging-based candidacy assessment, a physician-selected source when stem cell therapy fits, and a complete superbill for HSA, FSA, or out-of-network submission. Request a consultation or call (303) 997-1733.